A Research Guide for
DMD

In December 2025, the US Secretary of Health and Human Services approved adding DMD to the Recommended Uniform Screening Panel (RUSP). This is a landmark achievement that the DMD community has worked toward for years. It means that all states are now recommended to screen newborns for DMD as part of the standard heel-prick blood test done at birth.

What this means in practice:

• Minnesota has already begun screening newborns for DMD.
• Florida, Texas, and Arizona have announced intentions to implement screening programs.
• Other states are expected to follow, though timelines will vary — historically it takes states 2–5 years to add a new condition to their panels after RUSP addition.
• Screening typically uses a CK-based test on the newborn blood spot, with positive results confirmed by DMD gene testing.
• Early identification — before any symptoms — allows families to connect with care centers, begin cardiac and developmental monitoring, and start corticosteroids and mutation-specific treatments at the optimal time before significant muscle damage has occurred.

International newborn screening pilots are also active in the United Kingdom, Germany, the Netherlands, Belgium, Australia, and several other countries.

If your state is not yet screening and you have a family history of DMD or concerns about your child’s motor development, ask your pediatrician for a simple CK blood test. It is inexpensive, widely available, and can be done at any age.

A new DMD diagnosis has implications well beyond your son. Mothers may be carriers; sisters may be carriers; and grandmothers, aunts, and cousins through the maternal line may also need testing. About one third of DMD cases are caused by new (de novo) mutations not inherited from the mother, but two thirds are inherited.

A genetic counselor can help you understand:

• Your son’s specific mutation and what it means for his care
• Carrier testing for mothers and female relatives
• The chance that future children will be affected or carriers
• Reproductive options including preimplantation genetic testing (PGT) and prenatal testing
• Cardiac surveillance recommendations for confirmed carriers — this is critically important and often overlooked
• Resources for emotional and psychological support after diagnosis

The genetic report can look like a wall of numbers and abbreviations, but the parts that matter for treatment are understandable. The report will name the type of mutation — usually a deletion (missing piece), sometimes a duplication (extra copy) or a point mutation (a single-letter change, including "nonsense" mutations) — and which of the gene's 79 exons are involved (for example, "deletion of exons 48–50"). That exon information is the key that unlocks treatment eligibility: exon-skipping drugs each target one specific exon (44, 45, 51, or 53), so the report tells you directly whether an approved skipper applies. It will also show whether the change keeps the gene's "reading frame" in step (which tends to predict the milder Becker form) or throws it out of frame (classic Duchenne). And it flags two things that gate gene therapy: whether exon 8 or 9 is involved (a contraindication for Elevidys) and, separately, an antibody blood test done before treatment. You do not need to interpret all of this yourself — that is what your neuromuscular team and genetic counselor are for — but asking them to walk you through your son's specific report, and keeping a copy to bring everywhere, puts you in a far stronger position in every treatment conversation.

If you take one practical step after diagnosis, make it this: get connected to a specialized neuromuscular center — an MDA Care Center or a PPMD Certified Duchenne Care Center — rather than managing DMD through general pediatrics alone. DMD care is genuinely multidisciplinary: it weaves together neurology, cardiology, pulmonology, orthopedics, physical and occupational therapy, genetics, endocrinology, and mental health, and the survival gains of the modern era come substantially from having that whole team working in a coordinated way on a proactive schedule. A specialized center knows when to start steroids, when to begin cardiac imaging before any symptoms, when to introduce breathing support, and which clinical trials your son might fit — the kind of anticipatory timing that is hard to reproduce piecemeal. For families far from such a center, a common and effective model is "hub and spoke": routine care (steroid monitoring, therapy, school paperwork) close to home, with an annual comprehensive visit and the big treatment decisions made at the academic center. Asking for that referral early, and registering with a patient registry like TREAT-NMD or DuchenneConnect, opens both better coordinated care and access to research.

• What is the exact mutation in my son’s DMD gene? Can I have a written copy of the genetic report?
• Is this classic Duchenne or could it be Becker muscular dystrophy?
• Based on this mutation, which approved therapies (exon-skipping, gene therapy) is he eligible for?
• Are there current clinical trials specifically for his mutation type?
• Does his mutation fall in the exon 45–55 region that CRISPR trials might address?
• Should I and other female family members be tested as carriers?
• Do you recommend baseline cardiac imaging for me or any female relatives identified as carriers?
• Has our state begun newborn screening for DMD? If I have another child, will they be screened automatically?
• Will we be referred to a specialized neuromuscular center for ongoing care?
• Can you refer us to a genetic counselor experienced with DMD?

The oldest and least expensive option. Used worldwide for decades. Typical dose is around 0.75 mg/kg per day, though many centers also use intermittent (weekend-only) regimens. Effective, but causes the most weight gain and Cushingoid features (rounded face, increased appetite) of the three options. Other side effects include bone density loss, vertebral fractures, cataracts, mood and behavior changes, growth suppression, and adrenal suppression.

FDA-approved in 2017 specifically for DMD. Many neuromuscular specialists consider it the standard daily option in the US. Typically dosed around 0.9 mg/kg per day. Compared to prednisone, deflazacort tends to cause less weight gain but more growth suppression and more cataracts. The international FOR-DMD trial showed broadly similar efficacy to prednisone with somewhat different side effect tradeoffs. It is significantly more expensive than prednisone but has manufacturer copay assistance programs.

FDA-approved in October 2023 for boys age 2 and older with DMD; EMA approved December 2023; UK MHRA approved January 2024. Vamorolone is a dissociative steroid — designed to keep the anti-inflammatory and muscle-protecting effects of traditional steroids while reducing the metabolic and bone-related side effects.

Updated data presented at MDA 2026: Up to 8 years of treatment data now confirms that vamorolone provides comparable long-term effectiveness to deflazacort and prednisone on motor function measures, with significantly improved safety on key outcomes:

• Vertebral fracture rate: Significantly lower with vamorolone versus traditional steroids (p=0.0061)
• Growth preservation: Boys on vamorolone maintained normal growth trajectories, a highly significant difference versus deflazacort and prednisone (p<0.0001)
• Cataracts: Fewer cataracts compared to deflazacort (p<0.015)
• Vamorolone is the first dissociative corticosteroid to demonstrate preserved normal growth without compromising efficacy over this length of follow-up

Important considerations: vamorolone is expensive, and insurance coverage varies. Whether it is the right first-line steroid, a switch from another steroid due to side effects, or one to start at a younger age (approved from age 2) is a discussion with your neuromuscular team. For families concerned about bone health and growth — particularly in younger boys starting treatment — the 8-year safety data represents a meaningful advantage.

If your son takes any of the three steroids long-term, there is one safety concept that matters more than all the others combined: stress dosing. Long-term steroids quiet the body's own adrenal glands, so during a serious physical stress — a high fever or significant illness, an injury, an operation, or after vomiting that prevents him keeping the medicine down — his body cannot make the surge of stress hormone it needs. Without extra steroid he can develop an adrenal crisis, which is a genuine emergency (severe weakness, vomiting, low blood pressure, and in the worst case collapse). The protection is simple and your team will give you exact instructions: temporarily increase the oral dose (often roughly tripling it for a few days) during febrile illness or injury, and use an emergency injection of hydrocortisone if he cannot keep oral medicine down or is seriously unwell. Three things make this reliable: have the written stress-dosing plan and an emergency injection kit on hand before you need them, make sure your son wears a medical alert ID noting chronic steroid use, and give a copy of the plan to school staff and to any emergency department, since ER teams unfamiliar with DMD may not know to stress-dose. This is the single most important thing to learn cold — and never stop steroids abruptly on your own, as that itself can trigger a crisis.

Steroids work, but they ask something of the whole family day to day, and knowing what to expect helps you manage it rather than be blindsided. Increased appetite and weight gain are among the most visible effects — working with a dietitian early, before weight becomes a problem, is far easier than reversing it later, and matters because extra weight makes mobility, the heart, and breathing all harder. Mood, irritability, and sleep can shift, especially in the first weeks and around dose changes; tracking these and sharing them with the team sometimes leads to a helpful timing or dose adjustment. Behind the scenes, the routine protects against the slower effects: vitamin D and calcium for bones, an annual eye exam for cataracts, periodic bone-density scans, and blood pressure and blood sugar checks at visits. None of this means the side effects are reasons to stop — for almost every boy with DMD the benefit clearly outweighs them — but it does mean steroid care is active, not set-and-forget. If a particular side effect becomes hard to live with, that is exactly the moment to ask about switching among the three options rather than quietly struggling or skipping doses, since the agents differ meaningfully in their side-effect profiles.

• When is the right time to start steroids for my son?
• Which steroid do you recommend — deflazacort, prednisone, or vamorolone — and why?
• Given the 8-year vamorolone data on bone health and growth, should we consider starting with vamorolone?
• What is the dosing schedule (daily, weekend, every-other-day)?
• What side effects should we watch for, and how will we monitor them?
• Does insurance cover deflazacort or vamorolone? If not, what is the appeal process or patient assistance program?
• How should we manage doses during illness or before surgery (stress dosing)?
• When and how would we consider switching steroids if side effects are a problem?
• Can we combine corticosteroids with givinostat (Duvyzat)?
• How do we monitor bone density, and what are the thresholds for starting bisphosphonates?

Developer: Avidity Biosciences  |  Status: FDA Breakthrough Therapy designation (August 2025); BLA (application for approval) planned

Del-zota is the first Antibody Oligonucleotide Conjugate (AOC) for DMD. Unlike current exon-skipping drugs that primarily reach skeletal muscle, del-zota uses an antibody to deliver the exon-skipping molecule directly into both skeletal muscle and heart muscle. This is a critical advance because cardiac disease is the leading cause of death in DMD and current exon skippers do not meaningfully treat the heart.

Del-zota targets exon 44 skipping, which is amenable to approximately 8% of DMD patients. It is given by IV infusion. If approved, it would be the first exon 44–skipping therapy and the first to demonstrate cardiac dystrophin restoration.

Developer: Dyne Therapeutics  |  Status: Phase 3 FORZETTO trial enrolling; BLA filing planned end of June 2026

Z-rostudirsen is a next-generation exon 51 skipper designed to achieve significantly higher dystrophin levels than eteplirsen (the first-generation exon 51 drug approved in 2016). The Phase 3 FORZETTO trial is enrolling ambulatory boys ages 4–18.

Phase 1/2 DELIVER trial data showed increased dystrophin expression in muscle biopsies and positive trends on functional measures. If approved through accelerated approval, it would represent a meaningful upgrade for the approximately 13% of DMD boys amenable to exon 51 skipping.

Developer: Capricor Therapeutics  |  Status: PDUFA target date August 22, 2026

Deramiocel is a potential first cell therapy for DMD cardiomyopathy. It uses cardiosphere-derived cells (CDCs) — heart-derived cells that reduce inflammation and fibrosis in heart muscle when infused intravenously.

The Phase 3 HOPE-3 trial met its primary endpoint, showing improvement in upper-limb performance and cardiac ejection fraction. This is significant because no currently approved DMD therapy specifically targets the heart, yet cardiac disease is the leading cause of death. The FDA decision is expected by August 2026.

Developer: REGENXBIO  |  Status: Phase III AFFINITY DUCHENNE met primary endpoint May 2026; targeting accelerated approval 2027

RGX-202 is a next-generation AAV gene therapy with a novel micro-dystrophin construct that includes the C-Terminal domain — a portion absent from Elevidys’s micro-dystrophin. This structural difference may provide better muscle protection.

In May 2026, the Phase III AFFINITY DUCHENNE trial reported that 93% of participants reached ≥10% micro-dystrophin expression at Week 12, meeting the primary endpoint. If approved, RGX-202 could offer an alternative gene therapy option, potentially with an improved safety profile compared to AAVrh74-based products like Elevidys.

Developer: Precision BioSciences  |  Status: IND cleared February 2026; Phase 1/2 FUNCTION-DMD study enrolling

PBGENE-DMD is a CRISPR-based gene editing therapy that targets exons 45–55 of the DMD gene. This approach covers approximately 60% of boys with DMD — far more than any single exon-skipping drug. It uses dual ARCUS nucleases to make permanent edits to the DNA, allowing production of a near-full-length dystrophin protein.

Unlike gene therapy (which delivers a new mini-gene that may degrade over time) or exon-skipping drugs (which require lifelong weekly infusions), gene editing aims for a one-time permanent correction at the DNA level. The Phase 1/2 study is enrolling at Arkansas Children’s Hospital. This is early-stage but represents one of the most scientifically exciting approaches in the pipeline.

Developer: HuidaGene Therapeutics  |  Status: First patient dosed in MUSCLE trial (NCT06594094)

HG302 uses a newer CRISPR system called Cas12Max to target exon 51. The MUSCLE trial is enrolling boys ages 4–8. This is another early-stage gene editing approach, notable for using a different CRISPR enzyme than the more commonly used Cas9, which may offer advantages in editing efficiency or specificity.

• Ataluren (Translarna): For boys with nonsense mutations (about 10–15% of DMD). Was approved in Europe for years but EMA marketing authorization was not renewed due to disputed efficacy data. It was never FDA-approved, and PTC withdrew its US application in February 2026.
• Vesleteplirsen: Peptide-conjugated PMO (next-generation exon 51 skipper by Sarepta) that may achieve significantly higher dystrophin levels than eteplirsen. In trials.
• EDG-5506 (sevasemten): A novel fast skeletal myosin inhibitor designed to protect muscle from contraction damage. In trials for DMD and Becker.
• Utrophin upregulation: Utrophin is a protein similar to dystrophin that might compensate for its absence. Drugs aiming to boost utrophin are in earlier stages of development.
• Cardiac-targeted gene therapies: Several programs are developing gene therapies specifically designed to protect the heart in DMD, addressing a critical unmet need.
• Anti-fibrotic agents: Various agents targeting muscle fibrosis and inflammation continue to be studied.

Gene therapy was, for a time, framed as the breakthrough that would change everything, and the 2025 events make a more careful conversation necessary. Here is a grounded way to hold it. First, the safety news was serious and specific: the fatal liver failures occurred in non-ambulatory boys, and the FDA responded by removing that group from the approved label, adding its strongest (Boxed) warning, and making certain mutations (exon 8/9 deletions) and prior antibodies absolute reasons not to treat. For an eligible ambulatory boy aged 4 or older, the three-year data still show a substantial slowing of decline — the strongest long-term signal for any DMD gene therapy — but it slows the disease rather than curing or reversing it. Second, this is a one-time, irreversible decision in a way a daily pill is not: the infusion cannot be undone, it generally cannot be repeated, and receiving it may close the door on future gene therapies because of the immune response it provokes. That is why it deserves a genuine, unhurried discussion at an experienced center — weighing your son's specific trajectory, the monitoring commitment (including weekly blood tests for a period afterward), and the known risks including the fatal ones — rather than a fear-of-missing-out rush. It is completely reasonable to ask how this center has handled the new monitoring requirements, what they would do if liver tests rose, and whether waiting for emerging alternatives (such as RGX-202) might suit your son.

The list of experimental therapies — del-zota, z-rostudirsen, deramiocel, RGX-202, PBGENE-DMD, HG302, sevasemten and more — can feel like an alphabet soup that is impossible to keep up with. A simpler way to read it is to notice that nearly all of these are trying to fix one of three specific shortcomings of today's treatments. Some are about better delivery — getting more of the drug into muscle, and crucially into the heart, which current exon-skippers barely reach (del-zota and the cardiac cell therapy deramiocel are the clearest examples, and the heart matters because it is the leading cause of death). Some are about reaching more boys — CRISPR editing approaches like PBGENE-DMD aim to help the roughly 60% of boys whose mutations fall in one region, far more than any single exon-skipper. And some are about more or longer-lasting dystrophin than the first generation achieved. You do not need to track every program. The practical questions are simply: does any trial match my son's specific mutation and ambulatory status, is a site within reach, and how do its risks and time commitment compare with established care? Your neuromuscular center and a registry like TREAT-NMD can answer the matching question, and a healthy dose of "promising but unproven until the functional data are in" protects you from both false hope and false despair.

Setting honest expectations protects you from both disappointment and missed opportunity. The most important thing to understand is that today's disease-modifying treatments — steroids, exon-skipping drugs, gene therapy, givinostat — slow the disease; they do not stop or reverse it, and they do not yet add up to a cure. That is not a reason for discouragement: slowing the disease is genuinely valuable, it has extended both walking years and overall life expectancy, and it is layered on top of the cardiac and respiratory care that has transformed survival. But it does mean that a realistic frame — “we are buying time and function, and protecting the heart and lungs, while better treatments keep arriving” — serves families better than expecting any single therapy to be the answer. The corticosteroid backbone delivers the most established benefit; the mutation-directed therapies add incremental gains whose size is still being defined; and the richest pipeline in the disease's history means the standard of care is a moving target, with multiple regulatory decisions expected in 2026–2027. The healthiest stance combines genuine hope with realism: pursue the proven foundation rigorously, evaluate new options as they mature with clear eyes about the evidence, and measure success not only in milestones preserved but in a life lived as fully as possible at every stage.

• Based on my son’s exact mutation, which approved exon-skipping drug (if any) is he eligible for?
• Is my son a candidate for Elevidys gene therapy? Does his mutation involve exon 8 or 9?
• Given the November 2025 safety updates and 3-year efficacy data, how do you weigh the risks and benefits of Elevidys for my son?
• What is the AAV antibody testing process, and what happens if he is positive?
• Is he old enough to add givinostat (Duvyzat) to his regimen? What do we know about the reported deaths?
• Would a next-generation exon skipper (del-zota for exon 44, z-rostudirsen for exon 51) be an option for him, and are there trial sites near us?
• Is his mutation in the exon 45–55 range that CRISPR therapies (PBGENE-DMD) could address?
• Is deramiocel (CAP-1002) for his heart something we should be tracking?
• Are there any open clinical trials at our center or within traveling distance for his specific mutation?
• How do we weigh experimental approaches versus established care?
• If he receives gene therapy, can he still take exon-skipping drugs or other therapies afterward?

It can feel strange to take your son for heart scans and breathing tests when he seems fine, but that is exactly the point — in DMD, the heart and breathing muscles weaken quietly, long before anyone notices a symptom. The heart's dystrophin deficiency causes gradual scarring that a cardiac MRI can detect years before the heart's pumping strength drops, which is why doctors start medicines like ACE inhibitors around age 10 (sometimes earlier) before there is any visible heart problem: the goal is to protect the heart while it is still strong, not to rescue it after it weakens. Breathing follows a similar pattern, particularly after a boy stops walking — the muscles weaken so gradually that the body adapts and the change is easy to miss until a routine breathing test shows it, which is why cough-assist machines, breath-stacking, and overnight breathing support (BiPAP) are introduced on a schedule rather than waiting for a crisis. Understanding this reframes all those "well-child" appointments: they are not over-cautious box-ticking but the very interventions that turned DMD from a disease that took most boys in their teens into one where many men live well into adulthood. The appointments that feel unnecessary because your son seems fine are precisely the ones doing the quiet, life-extending work.

For many families, the move to a wheelchair looms as one of the most dreaded milestones — and it is often less frightening in reality than in anticipation, especially when planned ahead rather than forced by a crisis. The shift usually happens gradually: first a manual or power chair for long distances and outings while your son still walks at home and school, then, over time, a full-time power chair. Counterintuitively, getting a chair earlier for distances frequently increases what a boy can do — it conserves the energy he would otherwise spend on exhausting, fall-prone walking, lets him keep up with friends, and reduces injury risk — so it is better thought of as a tool for independence than as a loss. A power chair with tilt, recline, and seat-elevation features, custom-fitted by an experienced seating specialist, also protects posture, comfort, breathing, and skin. Planning ahead matters because the equipment, insurance approval, and home and vehicle modifications take time to arrange; starting those conversations before the chair is urgently needed prevents a stressful gap. Emotionally, it helps to name the transition openly, involve your son in choosing his chair, and frame it honestly: it changes how he gets around, not who he is or what he can pursue. Many young men describe the power chair, in hindsight, as the thing that gave them their independence back.

• When should my son start cardiac MRI monitoring?
• At what ejection fraction or imaging findings do you recommend starting heart medications?
• Is deramiocel (CAP-1002) something we should discuss for his cardiac care?
• How often should pulmonary function tests and sleep studies be done?
• When should we get a cough assist device for home use?
• What is his current bone density, and are we doing enough to protect his bones?
• Given the vamorolone bone fracture data, should we consider switching his steroid?
• Should he be evaluated for scoliosis, and at what point would surgery be considered?
• Is his growth on track, or should we consider endocrinology referral?
• Has he been screened for learning differences, ADHD, or anxiety?
• Do you recommend neuropsychological testing?
• Should female carriers in our family have cardiac evaluations?

Mobility needs evolve, often faster than families expect. Planning ahead rather than reacting in crisis makes transitions smoother:

• Early years: Ankle-foot orthoses (AFOs) at night, sometimes during the day. Manual gait aids if helpful. Physical therapy focused on stretching and maintaining range of motion.
• Mid school years: A manual or power wheelchair for distances and outings, well before full-time wheelchair use. This conserves energy, reduces falls, and helps boys keep up with peers.
• Transition to full-time wheelchair: Usually a power wheelchair with tilt, recline, and elevation features. This is a significant transition emotionally as well as physically. Custom fitting by an experienced seating specialist is essential for comfort and function.
• Upper body weakness: Robotic arm supports (such as JACO or Kinova arms), mounted devices, computer access technology, eye-tracking systems, and voice-controlled smart home systems become important tools for independence.
• Home modifications: Wheelchair ramps, accessible bathrooms (roll-in showers, ceiling lifts), wider doorways, accessible bedrooms on the main floor. A home accessibility assessment by an occupational therapist is invaluable.
• Vehicles: Adapted vans with ramps or lifts. Some young adults with sufficient upper body function may use adapted driving controls.

Equipment funding sources include insurance, Medicaid, MDA equipment assistance programs, CureDuchenne equipment grants, state assistive technology programs, and local service organizations (Lions Club, Kiwanis).

Children with DMD are entitled to educational accommodations and services under federal law in the US. The two main tools:

• 504 Plan: Covers accommodations like extra time on tests, reduced writing requirements, accessible bathrooms, elevator access, modified PE, and accessible transportation.
• Individualized Education Program (IEP): A more comprehensive plan for students who qualify for special education services. Particularly useful when DMD-associated learning differences, attention issues, or autism spectrum traits are present.

Specific things to advocate for:

• Accessible classrooms on the ground floor or reliable elevator access
• Reduced or modified handwriting requirements; access to a laptop, tablet, or voice dictation
• Excused or modified physical education with therapeutic alternatives
• Bathroom access and assistance plans
• Emergency evacuation plan written into the 504 or IEP
• Counseling support; peer education when helpful
• Extra time for transitions between classes
• A backup plan for fatigue days
• Transition planning starting at age 14–16 toward post-secondary goals

Many DMD therapies are extraordinarily expensive. Elevidys list price is over $3 million per dose; exon-skipping drugs cost hundreds of thousands of dollars per year; vamorolone and givinostat are also costly. Even with insurance, getting these covered often requires significant advocacy:

• Documentation from a specialized neuromuscular center (letters of medical necessity)
• Prior authorization and often multiple appeals
• Patient assistance programs from drug manufacturers — most have them; always ask
• Copay assistance programs and foundations
• State Medicaid coverage in addition to private insurance (many DMD families qualify based on the child’s disability, not family income)
• Working with a hospital social worker who specializes in rare disease insurance navigation

Patient advocacy organizations like Parent Project Muscular Dystrophy and MDA have dedicated insurance specialists who can help with denials and appeals. NORD also has financial assistance programs for qualifying families.

One of the most hopeful changes in DMD is that this is no longer just a pediatric disease. Young men with DMD increasingly attend college, work, build careers, form relationships, and live with meaningful independence. Planning for adulthood should begin well before the 18th birthday:

• Transition to adult care: Many specialized neuromuscular centers now have dedicated adult DMD clinics. Start the transition conversation around age 16, with the actual transfer often happening between 18 and 21. Ensure there is no gap in cardiac, respiratory, or orthopedic follow-up during the transition.
• Higher education and employment: Many young men with DMD pursue careers in technology, creative fields, knowledge work, advocacy, and education. Vocational counseling, state vocational rehabilitation services, and workplace accommodations are key resources.
• Independent and assisted living: Some young men live with parents lifelong; others move to accessible apartments with paid caregivers. Options range from family caregiving to home health aides to supported living communities. Start researching and planning early.
• Relationships and intimacy: An important and often underdiscussed part of life. Open conversations with the medical team about sexual health, fertility, and family planning are appropriate as your son becomes a young adult.
• Advance care planning: Difficult but important conversations about ventilation, resuscitation, and end-of-life wishes are best held while everyone is well and able to speak freely. These conversations evolve over time and should be revisited periodically.

Caring for a child with DMD is one of the hardest things a family will do. Caregiver burnout is real, common, and not a sign of weakness. Some hard-earned wisdom from the DMD community:

• You are not alone. Other DMD families have walked this path; many will share what they have learned. Connect through MDA, PPMD, CureDuchenne, and online communities.
• Get respite. Whether through family, friends, or paid respite services, regular breaks are not a luxury — they are how you sustain care over a decade and more.
• Siblings need their own space. Brothers and sisters carry their own grief and worries, often quietly. Build in time and attention for them, and consider sibling support groups offered by MDA and other organizations.
• Marriage and partnerships under strain. The diagnosis affects every relationship. Couples counseling early — before crisis — helps many families.
• Mental health matters — for everyone. Depression and anxiety are common in parents, siblings, and the young man with DMD himself. Professional support is appropriate and helpful.
• Document everything. Keep a binder or digital file with diagnoses, medications, dose changes, genetic reports, equipment prescriptions, IEP/504 plans, and appointment notes. You will need this more than you think.
• Long-term legal and financial planning. Special needs trusts, guardianship or supported decision-making at age 18, ABLE accounts, Medicaid planning, Social Security disability — an attorney experienced in special needs planning is worth the consultation. Start this process years before age 18.
• Hope is not naive. The therapeutic landscape has changed dramatically in the last decade. CRISPR gene editing, next-generation gene therapies, cell therapies, and antibody-conjugated exon skippers are all in advanced trials. Living well today and planning thoughtfully for tomorrow are both reasonable.

It is easy, in the work of managing a serious condition, for a boy with DMD to become the person things are done to — appointments scheduled, decisions made, care given — rather than an active author of his own life. Protecting his independence and voice is part of good care, not separate from it. Practically, that means involving him in his own medical conversations at an age-appropriate level as he grows, letting him ask his own questions and gradually take ownership of his routine; it means choosing technology and equipment that expand what he can do himself — powered mobility, computer access, eye-gaze and voice control, smart-home tools — and framing each as an upgrade in independence rather than a marker of decline. It means supporting his interests, friendships, education, and ambitions as you would any child's, and resisting the pull to define him by the diagnosis. As he approaches adulthood, supported decision-making (a framework that helps a young adult make his own choices with trusted support, rather than removing his decision-making rights) is increasingly preferred over default guardianship where it fits. Boys and young men with DMD pursue education, careers, relationships, advocacy, and creative work; the most important thing the people around him can do is treat his goals as real and worth building toward.

Amid the medical intensity, it is easy to lose sight of the fact that a boy with DMD is, first, a child who needs friendship, play, and fun. A full childhood is not a distraction from DMD care — it is part of thriving, and it protects mental health for the whole family. Many activities are accessible or adaptable: swimming and water play are often ideal (gentle on muscles and freeing for mobility), and adaptive sports, gaming, music, art, coding, scouting, drama, and camps (including MDA Summer Camp, designed specifically for children with neuromuscular conditions) open doors to friendship and accomplishment. The guiding principle on exercise is to stay active in submaximal, enjoyable ways — swimming and cycling are good examples — while avoiding the kind of high-resistance or muscle-burning “eccentric” exertion that can accelerate damage in dystrophic muscle; your physical therapist can help find the right level. Equally important is protecting ordinary social life: birthday parties, sleepovers adapted as needed, friendships at school, and being included rather than set apart. Children take their emotional cues from the adults around them; when family life makes room for joy, friendship, and normal childhood milestones alongside the appointments, a boy with DMD is far more likely to grow up seeing himself as a whole person with a full life, not a patient.

The instinct after a DMD diagnosis is to pour everything into your child, and the hardest lesson many families learn is that you cannot sustain a decade and more of caregiving on an empty tank. Your wellbeing is not a luxury that competes with your son's care — it is the foundation that makes that care durable. Depression and anxiety are common among parents and partners of children with DMD, and seeking professional support for yourself is a sign of strength and good planning, not failure. Build in respite from the start, whether through family, friends, or paid services; regular breaks are how caregiving is sustained, not a sign you love your child any less. Tend to your relationship if you have a partner — the diagnosis strains even strong partnerships, and couples who seek support early tend to fare better than those who wait for a crisis. Connect with other DMD families through MDA, PPMD, and CureDuchenne, who understand this road in a way few others can. And give yourself permission to feel the full range of emotions — grief, anger, fear, and also ordinary joy and pride — without judging yourself for any of them. A parent who is supported, rested, and not isolated is the single most valuable resource a child with DMD has.

As boys with DMD grow into young men — an expectation now, not an exception — their lives include the same questions about relationships, intimacy, and family that any adult navigates, and these deserve open, respectful conversation rather than avoidance. Disability does not erase the desire for connection, partnership, or a private adult life, and supporting a young man's autonomy here is part of seeing him as a whole person. Practical points worth raising with the medical team as he matures: physical intimacy is possible and worth discussing frankly, including how mobility, fatigue, and equipment factor in; privacy and dignity around personal care matter and can be planned for; and questions of fertility and family planning are appropriate to explore with specialists when relevant. These are not conversations most families anticipate at diagnosis, but they reflect the genuinely changed trajectory of the disease — one where planning for an adult life, including its relational and intimate dimensions, is realistic. A good neuromuscular center, and increasingly dedicated adult DMD clinics, can help open these discussions in a way that respects the young man's privacy and adulthood. Treating these milestones as normal and worth supporting, rather than as off-limits, is part of helping a young man with DMD build the full life that modern care now makes possible.

• When and how should we plan for the transition to a wheelchair?
• What equipment does my son need now, and what should we anticipate next?
• Can you help us with documentation for home modifications?
• What school accommodations do you recommend, and can you provide supporting letters?
• How do we manage stress dosing of steroids during illness, surgery, or injury?
• What is your plan for transitioning his care to an adult neuromuscular center?
• Are there clinical research opportunities in our region we should consider?
• What mental health resources do you recommend for our family?
• Can you connect us with a social worker who knows DMD and insurance navigation?
• Where can we connect with other DMD families locally?

• FORZETTO (Dyne, NCT07608432) — Phase 3 trial of z-rostudirsen, next-generation exon 51 skipper. Ambulatory boys ages 4–18. BLA filing planned end of June 2026.
• AFFINITY DUCHENNE (REGENXBIO, NCT05693142) — Phase III of RGX-202 gene therapy. Met primary endpoint May 2026.
• EMBARK (Sarepta, NCT05096221) — Phase 3 Elevidys gene therapy pivotal trial; 3-year follow-up data showed ~70% reduction in functional decline.
• FUNCTION-DMD (Precision BioSciences, NCT07429240) — Phase 1/2 of PBGENE-DMD CRISPR gene editing for exons 45–55. Enrolling at Arkansas Children’s Hospital.
• MUSCLE (HuidaGene, NCT06594094) — CRISPR/Cas12Max gene editing (HG302) for exon 51. Boys ages 4–8.
• HOPE-3 (Capricor, NCT05126758) — Phase 3 of deramiocel (CAP-1002) for cardiomyopathy. Met primary endpoint; FDA decision expected August 2026.
• EXPLORE44 (Avidity, NCT05670730) — Phase 1/2 of del-zota (AOC) for exon 44 skipping with cardiac delivery. FDA Breakthrough Therapy designation Aug 2025; BLA planned.
• EPIDYS (ITF Therapeutics, NCT02851797) — Pivotal trial of givinostat (Duvyzat); open-label extension ongoing with 207 patients.
• ESSENCE (Sarepta, NCT02500381) — Confirmatory trial for golodirsen and casimersen exon-skipping therapies.

Boys and young men with DMD have specific emergency needs. Prepare in advance:

• Medical alert ID: Should note DMD diagnosis, chronic steroid use (requires stress dosing), cardiac status, and ventilation needs.
• Emergency medication kit: Stress-dose steroids (injectable hydrocortisone and/or oral prednisone emergency dose), along with a written letter from the neuromuscular team specifying dosing instructions for emergency providers who may be unfamiliar with DMD.
• Emergency letter: A one-page emergency protocol from the neuromuscular center that can be shown to ER staff. Should cover: no succinylcholine (risk of fatal hyperkalemia), cautious use of anesthesia, stress dosing protocol, ventilation needs, and cardiac precautions.
• Power backup: For boys and young men on ventilators or other powered medical equipment, have a battery backup system and a plan for extended power outages.
• Hospital bag: Keep a packed bag with insurance cards, medication list, genetic report, emergency letter, and basic supplies ready.

A DMD diagnosis makes families understandably hungry for hope, and the internet is full of supplements, clinics, and “protocols” that promise more than they can deliver — some merely a waste of money, some genuinely harmful or a dangerous distraction from proven care. A few habits protect you. Be wary of anything that claims to cure DMD, that tells you to stop or replace steroids and standard care, that relies on testimonials and before-and-after stories rather than published trials, or that asks you to pay out of pocket for an unproven “stem cell” or infusion treatment at a clinic outside the normal medical system — unregulated stem-cell offerings in particular have harmed patients and have no proven benefit in DMD. Ask where the claim's evidence comes from: a recognized organization (MDA, PPMD, CureDuchenne) or a peer-reviewed study, or a sales page? Remember that even genuinely promising therapies in this guide are described honestly as slowing the disease, not reversing it, and that several once-hyped approaches failed when finally tested — which is exactly why trials matter. The safest move with anything you find is to bring it to your neuromuscular team and ask, plainly, “Is there real evidence for this, and is it safe alongside his current care?” A trustworthy source will never ask you to abandon proven treatment, and a good team will take your questions seriously rather than dismiss them.

Clinical trials are not a last resort — in a disease moving as fast as DMD, a well-chosen trial can be a route to tomorrow's therapy today, and registering your interest is worthwhile even if you are not ready to enroll. A few practicalities help. Eligibility is usually tight and specific: most trials require a particular mutation (a given exon), a certain age, and a defined ambulatory status, which is another reason the written genetic report matters so much. The best ways to find matching studies are to ask your neuromuscular center directly, search ClinicalTrials.gov for "Duchenne muscular dystrophy" filtered by recruiting status and location, and register with a patient registry such as TREAT-NMD or PPMD's DuchenneConnect, which exist specifically to connect families with research. When weighing a trial, ask what phase it is (earlier phases focus more on safety, later phases on whether it works), whether there is a placebo group and what happens afterward, what the time and travel commitment is, what is known about risks, and whether standard care continues alongside. It is also fair to ask whether participating in one study might affect eligibility for another later — this matters especially with gene therapy, which can close the door on future gene-based trials. Trials are voluntary, you can withdraw at any time, and choosing not to enroll never compromises your son's standard care. Approached with clear questions, a trial is simply one more option to evaluate alongside established treatment.

• Is our son registered with TREAT-NMD or DuchenneConnect to be matched with trials?
• Are there any clinical trials open at our center or within traveling distance right now?
• Can you provide an emergency protocol letter for ER visits?
• What is the stress-dosing protocol we should follow during illness or injury?
• Can you connect us with MDA, PPMD, or CureDuchenne for family support?
• What financial assistance programs should we apply for?
• When should we begin legal and financial planning (special needs trust, guardianship)?
• Are there any DMD family events or conferences coming up that you recommend?

Ataluren was developed by PTC Therapeutics for nonsense-mutation DMD, which accounts for roughly 10–15% of all DMD cases. It was designed to allow the cell’s protein-making machinery to “read through” a premature stop codon and produce functional dystrophin.

• EU conditional approval (July 2014): The European Medicines Agency (EMA) granted ataluren a conditional marketing authorization based on an initial Phase 2b trial (Study 007). This was one of the first DMD-specific approvals anywhere in the world. The authorization was conditional on PTC completing confirmatory trials.
• Confirmatory trials fail: The pivotal confirmatory trials — Study 020 and its extension Study 041 — did not meet their primary endpoints. The drug did not demonstrate a statistically significant benefit in the primary measure of the 6-minute walk test.
• EMA non-renewal (2023–2024): The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended non-renewal of the conditional marketing authorization after reviewing the totality of evidence. The committee concluded that the confirmatory data were insufficient to support continued approval.
• EU de-authorization (March 2025): The European Commission officially withdrew the marketing authorization for ataluren across all EU member states. Patients already on treatment were given transition plans.
• US — never approved: The FDA never approved ataluren. PTC Therapeutics submitted an NDA but withdrew its resubmission in February 2026, effectively ending the US regulatory pathway.

Ataluren represents an important case study: a therapy that was approved abroad based on early data, used by thousands of families, but ultimately did not demonstrate sufficient efficacy in confirmatory trials. Families should understand that conditional or accelerated approvals carry genuine uncertainty, and confirmatory data matters.

Viltolarsen is an exon 53-skipping antisense oligonucleotide developed through a collaboration between Nippon Shinyaku and the National Center of Neurology and Psychiatry (NCNP) in Japan. It is one of the clearest examples of international neuromuscular research leading to global approvals.

• Japan approval (March 2020): Japan’s Ministry of Health, Labour and Welfare approved viltolarsen, making it among the earliest exon-skipping drug approvals worldwide.
• FDA approval (August 2020): The FDA granted accelerated approval for viltolarsen for the treatment of DMD in patients with a confirmed mutation amenable to exon 53 skipping, approximately 8% of all DMD patients.

Viltolarsen’s journey from Japanese academic research to global availability illustrates the importance of international collaboration in rare disease drug development.

• TREAT-NMD: An international neuromuscular network that coordinates patient registries, clinical trial readiness, and care standards across more than 40 countries. Registering with TREAT-NMD is one of the most important steps a family can take to stay connected to global trial opportunities. treat-nmd.org
• UK DMD Hub: A National Institute for Health and Care Research (NIHR) initiative that maintains a UK-wide clinical trial finder for DMD and other neuromuscular conditions. The Hub connects UK families with active trials across the country. dmdhub.org
• World Duchenne Organization (WDO): A global umbrella organization connecting Duchenne parent organizations across more than 50 countries. WDO advocates at the EMA and WHO level, publishes global care standards, and hosts the annual World Duchenne Conference. worldduchenne.org

Ataluren was designed to allow cells to “read through” premature stop codons in the DMD gene, targeting roughly 10–15% of boys with nonsense mutations. It received conditional approval in Europe in 2014, but the confirmatory Phase 3 trials (Study 020 and Study 041) did not meet their primary endpoints. The EMA did not renew the marketing authorization, and the European Commission officially withdrew it in March 2025. PTC Therapeutics withdrew its FDA resubmission in February 2026. Thousands of families used ataluren for years in Europe before it was de-authorized — a reminder that conditional approvals carry genuine uncertainty.

Idebenone is a synthetic analog of coenzyme Q10, studied as an antioxidant to protect respiratory function in DMD. The Phase 3 DELOS trial showed a modest effect on respiratory decline in steroid-naïve patients, but a subsequent confirmatory trial (SIDEROS) in steroid-treated patients — the standard-of-care population — failed its primary endpoint. Santhera withdrew its EMA application in 2020 after the CHMP recommended against approval. Idebenone is not recommended for DMD in any major guideline.

Blocking myostatin — a protein that limits muscle growth — was a highly anticipated approach. Multiple companies pursued this. Pfizer’s domagrozumab (PF-06252616) failed to show functional benefit in the Phase 2/3 trial in DMD and was discontinued. Acceleron’s ACE-031 (a soluble activin receptor trap) was halted early due to nosebleeds and gum bleeding linked to effects on blood vessel formation. Despite strong preclinical rationale, no myostatin-pathway inhibitor has succeeded in DMD clinical trials.

Drisapersen was a 2’-O-methyl phosphorothioate antisense oligonucleotide targeting exon 51, developed by Prosensa/BioMarin. The FDA rejected the application in January 2016 due to insufficient evidence of clinical benefit and concerns about safety (injection-site reactions, renal toxicity, thrombocytopenia). BioMarin subsequently withdrew EU and US applications. The failure of drisapersen highlighted the importance of chemistry platform — the competing phosphorodiamidate morpholino oligo (PMO) platform used by eteplirsen had a better safety profile and went on to receive approval.

Elevidys gene therapy was briefly approved for non-ambulatory patients (June 2024 label expansion), but following two fatal cases of acute liver failure in non-ambulatory boys, the FDA removed the non-ambulatory indication entirely in November 2025. This was the first time the FDA reversed a DMD therapy indication. As of May 2026, Elevidys remains approved only for ambulatory boys age 4 and older. Sarepta is studying enhanced immunosuppression protocols that might enable future non-ambulatory access, but this is investigational.

Earlier decades saw attempts to use growth hormone and various anabolic agents to build muscle mass in DMD. These approaches were largely abandoned because increasing contractile demand on dystrophin-deficient muscle fibers can accelerate damage rather than build functional strength. Growth hormone is sometimes used in a targeted way for steroid-induced growth failure under endocrinology supervision, but it is not a treatment for DMD itself. Families should be cautious about any product marketed to “build muscle” in DMD — the biology of dystrophin-deficient muscle does not respond to these approaches the way healthy muscle does.

• Dystrophin — a large structural protein inside muscle cells that acts as a shock absorber, connecting the internal skeleton of the cell to its outer membrane. DMD is caused by mutations that prevent production of functional dystrophin.
• Exon skipping — a therapeutic strategy that uses short synthetic molecules (antisense oligonucleotides) to instruct the cell to skip over a specific mutated section (exon) of the DMD gene during protein production. The result is a shorter but partially functional dystrophin protein, similar to Becker muscular dystrophy.
• Nonsense mutation — a type of genetic mutation that creates a premature “stop sign” in the gene, causing the cell to halt protein production before a complete dystrophin molecule is made. Roughly 10–15% of DMD cases are caused by nonsense mutations.
• Reading frame — the way the cell reads the genetic code in groups of three letters. DMD deletions that disrupt the reading frame produce no usable dystrophin (Duchenne); deletions that preserve it produce a shortened but partly working protein (Becker). This distinction is fundamental to understanding why genetic testing is essential.
• CK (creatine kinase) — an enzyme found inside muscle cells. When muscles are damaged, CK leaks into the bloodstream. In DMD, CK levels are typically 10 to 100 times normal, and elevated CK is often the first laboratory clue to the diagnosis.
• Corticosteroid — a class of anti-inflammatory medication that is the proven backbone of DMD treatment. Corticosteroids slow muscle deterioration and prolong ambulation, but carry significant side effects including weight gain, bone fragility, and growth suppression.
• Deflazacort — a corticosteroid (brand name Emflaza) widely used in DMD. Tends to cause less weight gain than prednisone but has a higher rate of cataracts.
• Vamorolone (Agamree) — a dissociative corticosteroid approved for DMD in 2023. Designed to preserve the anti-inflammatory benefits of corticosteroids while reducing side effects on bone, growth, and metabolism. Now has up to 8 years of follow-up data.
• Gene therapy (AAV) — a treatment that uses an adeno-associated virus (AAV) as a delivery vehicle to carry a therapeutic gene into muscle cells. Because the full dystrophin gene is too large to fit inside an AAV, gene therapy delivers a miniaturized version called micro-dystrophin.
• Micro-dystrophin — a shortened, engineered version of the dystrophin gene that retains the most critical functional domains but is small enough to be packaged inside an AAV vector for gene therapy delivery. Elevidys delivers a micro-dystrophin construct.
• Ambulatory / non-ambulatory — ambulatory means the patient is still able to walk. Non-ambulatory means the patient uses a wheelchair full-time. This distinction is clinically important because it affects which treatments are available (e.g., the FDA narrowed Elevidys to ambulatory patients only in November 2025) and how disease progression is monitored.
• RUSP (Recommended Uniform Screening Panel) — the federally recommended list of conditions that states should screen for in all newborns. DMD was added to the RUSP in December 2025, a landmark milestone that will enable earlier diagnosis and earlier treatment.
• Elevidys (delandistrogene moxeparvovec) — the first and currently only FDA-approved gene therapy for DMD. Delivers micro-dystrophin via an AAVrh74 vector. Approved for ambulatory patients age 4 and older. Carries a Boxed Warning for liver injury as of November 2025.
• Givinostat (Duvyzat) — an oral histone deacetylase (HDAC) inhibitor approved for DMD in March 2024. Works by reducing the inflammation and fibrosis (scarring) that replace muscle tissue, rather than by restoring dystrophin. The first non-steroidal, non-gene-targeted oral therapy for DMD.

• University of Utah Neuromuscular Program (MDA Care Center): Comprehensive neuromuscular care for both pediatric and adult patients, with access to clinical trials. Located at University of Utah Health, Salt Lake City. — 801-585-6387 (Neurosciences)
• Primary Children’s Hospital: Pediatric neuromuscular clinic with integrated pediatric cardiology (cardiomyopathy program with cMRI capability), pulmonology, orthopedics, and rehabilitation services for DMD. Part of Intermountain Health, Salt Lake City. — 801-662-1000
• Intermountain Health: Regional pediatric neurology and cardiology referral pathways; outpatient infusion services supporting weekly exon-skipping therapy delivery. — 801-442-2000

• MDA Care Centers: The Muscular Dystrophy Association operates a nationwide network of multidisciplinary neuromuscular clinics. Find your nearest center at mda.org/care. — 1-833-ASK-MDA1 (1-833-275-6321)
• PPMD Certified Duchenne Care Centers: Parent Project Muscular Dystrophy certifies centers that meet specific standards for comprehensive Duchenne care. The certification program ensures access to genetic counseling, cardiology, pulmonology, physical therapy, and social services under one coordinated team. Find certified centers at parentprojectmd.org. — 1-800-714-5437
• Children’s National Hospital, Washington, DC: A leading neuromuscular center and major clinical trial site for DMD therapies. Home to the Center for Genetic Medicine Research. — 202-476-5000
• Cincinnati Children’s Hospital Medical Center: Major DMD research and care center with extensive clinical trial programs, including gene therapy and exon-skipping studies. — 513-636-4200
• Nationwide Children’s Hospital, Columbus, Ohio: Home to the Center for Gene Therapy and a key clinical trial site for multiple DMD gene therapy programs, including Elevidys and RGX-202. — 614-722-2000

• George E. Wahlen VA Medical Center, Salt Lake City: Neurology services for veterans with neuromuscular conditions; referral pathways to University of Utah neuromuscular specialists when specialized DMD care is needed. — 801-582-1565
• VA Neurology Services (national): Veterans with muscular dystrophy or neuromuscular conditions can access care through any VA medical center. VA neurology departments provide ongoing neuromuscular care, and referrals to specialized academic medical centers are available when needed. — 1-800-827-1000 (VA Health Benefits Hotline)

• Holland Bloorview Kids Rehabilitation Hospital, Toronto: Canada’s largest children’s rehabilitation hospital with a specialized neuromuscular clinic providing comprehensive DMD care including physiotherapy, respiratory management, and transition planning. — 416-425-6220
• The Hospital for Sick Children (SickKids), Toronto: A leading pediatric research hospital with a neuromuscular diseases clinic that offers diagnostic evaluation, genetic testing, multidisciplinary care, and access to clinical trials for DMD. — 416-813-1500
• Children’s Hospital of Eastern Ontario (CHEO), Ottawa: Pediatric neuromuscular program with multidisciplinary DMD care and genetic services. — 613-737-7600
• BC Children’s Hospital, Vancouver: Neuromuscular clinic and clinical trials program for DMD within the Provincial Health Services Authority. — 604-875-2345
• Montreal Children’s Hospital (McGill University Health Centre): Neuromuscular diseases program with DMD specialty care and research. — 514-412-4400
• Alberta Children’s Hospital, Calgary: Pediatric neuromuscular clinic with DMD care coordination. — 403-955-7211

• United Kingdom:
  • Great Ormond Street Hospital (GOSH), London: Dubowitz Neuromuscular Centre — one of the world’s leading pediatric neuromuscular programs and a major DMD clinical trial site. — +44 20 7405 9200
  • Newcastle upon Tyne Hospitals — John Walton Muscular Dystrophy Research Centre: UK North Star Network hub; birthplace of the NSAA outcome measure; adult and pediatric DMD care. — +44 191 233 6161
• Europe:
  • Universitätsklinikum Freiburg, Germany: Leading German neuromuscular center with DMD clinical trials and comprehensive multidisciplinary care. — +49 761 270 0
  • Hôpital Necker-Enfants Malades, Paris, France: Major pediatric neuromuscular center; key partner with AFM-Téléthon (one of the largest DMD research funders globally). — +33 1 44 49 40 00
  • Policlinico Gemelli, Rome, Italy: Centro Clinico NEMO network — Italian centers of excellence for neuromuscular disease care and givinostat research. — +39 06 3015 1
• Asia-Pacific:
  • National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan: Reference center for DMD in Japan; key site for viltolarsen development and Elevidys post-marketing studies. — +81 42 341 2711
  • Royal Children’s Hospital, Melbourne, Australia: Neuromuscular clinic with DMD specialty care and clinical trials. — +61 3 9345 5522
• Networks:
  • TREAT-NMD Network: Coordinates neuromuscular centers of excellence across more than 40 countries with standardized patient registries and harmonized care guidelines. treat-nmd.org
  • World Duchenne Organization (WDO): Connects Duchenne parent organizations and care centers across more than 50 countries. worldduchenne.org